tiprankstipranks
Regeneron, Sanofi announce EC approval of Dupixent
The Fly

Regeneron, Sanofi announce EC approval of Dupixent

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent in the European Union, or EU, to treat severe atopic dermatitis in children aged six months to five years old who are candidates for systemic therapy. With this approval, Dupixent is the first and only targeted medicine indicated to treat these young children in Europe and the U.S.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on REGN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles